Using a large language model to improve diagnosis of heart failure with preserved ejection fraction
Application of a Multimodal Large Language Model to Assist Diagnosis for Heart Failure With Preserved Ejection Fraction
This study is testing whether a new computer program can help doctors better diagnose heart failure with preserved ejection fraction by using different types of patient information.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06486649 on ClinicalTrials.gov |
What this trial studies
This observational study aims to validate the effectiveness of a multimodal large language model in screening for heart failure with preserved ejection fraction (HFpEF). It compares the model's diagnostic capabilities with traditional clinical assessments. The study integrates various data types, including medical records, imaging, and patient-reported symptoms, to enhance the understanding and diagnosis of HFpEF. By addressing the complexities of HFpEF diagnosis, the study seeks to reduce missed diagnoses and improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include cardiology inpatients aged 18-80 with suspected HFpEF and relevant symptoms.
Not a fit: Patients with acute heart failure or severe coronary stenosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier and more accurate diagnoses of heart failure with preserved ejection fraction, ultimately improving patient care.
How similar studies have performed: While the use of large language models in healthcare is emerging, this specific application for HFpEF diagnosis is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18-80 years, male or female; 2. Cardiology inpatients with suspected heart failure with preserved ejection fraction (cardiac ultrasound suggestive of LVEF ≥50% with at least 1 of the following: 1, left ventricular hypertrophy and/or left atrial enlargement; and 2, abnormal diastolic cardiac function); 3. Current or previous at least one symptom of heart failure, including dyspnea (including exertional dyspnea, nocturnal paroxysmal dyspnea, and telangiectasia), malaise, nausea, and bilateral lower extremity edema; 4. Voluntary participation and signed informed consent. Exclusion Criteria: 1. Acute heart failure or acute worsening of chronic heart failure; 2. Severe coronary stenosis (≥75% stenosis) without revascularization; 3. Patients who are unable to perform exercise stress echocardiography or have contraindications to the test; 4. are participating in other clinical trials; 5. Those with severe organic pathologies of the liver, kidney, or hematologic system or those with chronic diseases; 6. Those who are unable to follow the trial procedures; 7. Those who refuse to sign the informed consent.
Where this trial is running
Beijing, Beijing Municipality
- Peking UniversityThird Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Xiangbin Meng
- Email: 15896850171@163.com
- Phone: 17600220171
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.